These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24292683)

  • 1. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
    Kang Z; Yu Y; Zhu YJ; Davis S; Walker R; Meltzer PS; Helman LJ; Cao L
    Oncogene; 2014 Dec; 33(50):5697-705. PubMed ID: 24292683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.
    Makawita S; Ho M; Durbin AD; Thorner PS; Malkin D; Somers GR
    Pediatr Dev Pathol; 2009; 12(2):127-35. PubMed ID: 18788888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
    Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
    Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
    Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
    Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma.
    Tombolan L; Orso F; Guzzardo V; Casara S; Zin A; Bonora M; Romualdi C; Giorgi C; Bisogno G; Alaggio R; Pinton P; De Pittà C; Taverna D; Rosolen A; Lanfranchi G
    Am J Pathol; 2011 Nov; 179(5):2611-24. PubMed ID: 21924226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
    Cao L; Yu Y; Darko I; Currier D; Mayeenuddin LH; Wan X; Khanna C; Helman LJ
    Cancer Res; 2008 Oct; 68(19):8039-48. PubMed ID: 18829562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo.
    Tarnowski M; Tkacz M; Zgutka K; Bujak J; Kopytko P; Pawlik A
    BMC Cancer; 2017 Aug; 17(1):532. PubMed ID: 28793874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L).
    Mayeenuddin LH; Yu Y; Kang Z; Helman LJ; Cao L
    Oncogene; 2010 Dec; 29(48):6367-77. PubMed ID: 20818434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
    Myers AL; Lin L; Nancarrow DJ; Wang Z; Ferrer-Torres D; Thomas DG; Orringer MB; Lin J; Reddy RM; Beer DG; Chang AC
    Oncotarget; 2015 Sep; 6(28):25897-916. PubMed ID: 26317790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
    Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
    Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
    Abraham J; Prajapati SI; Nishijo K; Schaffer BS; Taniguchi E; Kilcoyne A; McCleish AT; Nelon LD; Giles FG; Efstratiadis A; LeGallo RD; Nowak BM; Rubin BP; Malempati S; Keller C
    Mol Cancer Ther; 2011 Apr; 10(4):697-707. PubMed ID: 21447712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
    J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
    Browne BC; Crown J; Venkatesan N; Duffy MJ; Clynes M; Slamon D; O'Donovan N
    Ann Oncol; 2011 Jan; 22(1):68-73. PubMed ID: 20647220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
    Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
    Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression.
    Zhao S; Wu L; Kuang Y; Su J; Luo Z; Wang Y; Li J; Zhang J; Chen W; Li F; He Y; Tao J; Zhou J; Xu X; Peng C; Chen X
    Int J Oncol; 2018 Dec; 53(6):2397-2408. PubMed ID: 30272281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
    BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
    Subbiah V; Naing A; Brown RE; Chen H; Doyle L; LoRusso P; Benjamin R; Anderson P; Kurzrock R
    PLoS One; 2011 Apr; 6(4):e18424. PubMed ID: 21494688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.